The role of KRT18 in lung adenocarcinoma development: integrative bioinformatics and experimental validation DOI Creative Commons
Yongjie Li, Min Zeng, Yanru Qin

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Dec. 27, 2024

Lung adenocarcinoma (LUAD) represents one of the most common subtypes lung cancer with high rates incidence and mortality, which contributes to substantial health economic demand across globe. Treatment today mainly consists surgery, radiotherapy, chemotherapy, but their efficacy in advanced stages is often suboptimal emphasizes clear need for new biomarkers therapeutic targets. Using comprehensive bioinformatics analyses consisting Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein (HPA) Clinical Proteomic Tumor Analysis Consortium (CPTAC), immune infiltration analysis functional enrichment analysis, single-cell we examined potential keratin 18 (KRT18) as a candidate biomarker LUAD. KRT18 was significantly elevated LUAD tissue relative normal adjacent (p < 0.05), its expression correlated poor clinical-pathological features inferior prognostic outcome. Furthermore, associated several populations cells, suggesting may contribute local tumor microenvironment potentially pathways evasion. Survival indicated that overall survival (OS), disease-specific (DSS), progression-free interval (PFI), reinforcing legitimacy tool (AUC = 0.846). Importantly, gene found KRT18-associated genes enriched lymphocyte differentiation response pathways, provides mechanistic insight into biological effects attributed KRT18. Notably, NU.1025 has demonstrated capability reversing KRT18-modulated oncogenic features, targeted strategies can be developed moving forward. In conclusion, our data demonstrate utility also serve target merit further investigation underlying functions roles clinic.

Language: Английский

The role of KRT18 in lung adenocarcinoma development: integrative bioinformatics and experimental validation DOI Creative Commons
Yongjie Li, Min Zeng, Yanru Qin

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Dec. 27, 2024

Lung adenocarcinoma (LUAD) represents one of the most common subtypes lung cancer with high rates incidence and mortality, which contributes to substantial health economic demand across globe. Treatment today mainly consists surgery, radiotherapy, chemotherapy, but their efficacy in advanced stages is often suboptimal emphasizes clear need for new biomarkers therapeutic targets. Using comprehensive bioinformatics analyses consisting Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein (HPA) Clinical Proteomic Tumor Analysis Consortium (CPTAC), immune infiltration analysis functional enrichment analysis, single-cell we examined potential keratin 18 (KRT18) as a candidate biomarker LUAD. KRT18 was significantly elevated LUAD tissue relative normal adjacent (p < 0.05), its expression correlated poor clinical-pathological features inferior prognostic outcome. Furthermore, associated several populations cells, suggesting may contribute local tumor microenvironment potentially pathways evasion. Survival indicated that overall survival (OS), disease-specific (DSS), progression-free interval (PFI), reinforcing legitimacy tool (AUC = 0.846). Importantly, gene found KRT18-associated genes enriched lymphocyte differentiation response pathways, provides mechanistic insight into biological effects attributed KRT18. Notably, NU.1025 has demonstrated capability reversing KRT18-modulated oncogenic features, targeted strategies can be developed moving forward. In conclusion, our data demonstrate utility also serve target merit further investigation underlying functions roles clinic.

Language: Английский

Citations

0